Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00315211 · ClinicalTrials.gov registry record · Phase 2
Weekly Topotecan With Docetaxel in Recurrent Small Cell Lung Cancer
A Phase 2 study, sponsored by Aultman Health Foundation.
- Terminated
- Registry status
- Phase 2
- Development phase
- 7
- Enrollment target
NCT00315211 is a Phase 2 study that was terminated before completion, run by Aultman Health Foundation. The registered enrollment target is 7 participants.
The verdict
NCT00315211, a Phase 2 study, was terminated before completion, sponsored by Aultman Health Foundation.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 7 participants
- Enrollment target
Study Summary
The purposes of this study are: * To determine the overall response rate of patients treated with at least 2 cycles of this regimen. * To determine the feasibility and toxicity of the combination of topotecan and docetaxel.
Interventions
- DRUG Intravenous Topotecan
- DRUG Intravenous Docetaxel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2004-11 |
| Est. Completion | 2007-11-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00315211
The ClinicalTrials.gov registry entry for NCT00315211 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aultman Health Foundation, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Intravenous Topotecan is the first listed.
NCT00315211 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00315211 about?
NCT00315211 is a clinical study titled "Weekly Topotecan With Docetaxel in Recurrent Small Cell Lung Cancer". The purposes of this study are: * To determine the overall response rate of patients treated with at least 2 cycles of this regimen. * To determine the feasibility and toxicity of the combination of topotecan and docetaxel.
What is the current status of trial NCT00315211?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 7 participants. The study started on 2004-11. Estimated completion is 2007-11-08.
What interventions are being tested in trial NCT00315211?
The interventions under investigation include: Intravenous Topotecan (DRUG), Intravenous Docetaxel (DRUG).
Who is sponsoring clinical trial NCT00315211?
This trial is sponsored by Aultman Health Foundation, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.